Trial watch: Dendritic cell-based anticancer therapy

OncoImmunology

Volumn 3, Issue 11, 2014, Pages e963424-1-e963424-16

  Bloy, Norma ^a,b,c,d   Pol, Jonathan ^a,b,c   Aranda, Fernando ^a,b,c   Eggermont, Alexander ^a   Cremer, Isabelle ^b,c,e   Fridman, Wolf Hervé ^b,c,e   Fučíková, Jitka ^f,g   Galon, Jérôme ^b,c,e,h   Tartour, Eric ^b,h,i   Spisek, Radek ^f,g   Dhodapkar, Madhav V ^j   Zitvogel, Laurence ^a,b   Kroemer, Guido ^a,b,c,h,i   Galluzzi, Lorenzo ^a,b,c,h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f CHARLES UNIVERSITY   (Czech Republic)

^g Sotio Biotech as   (Czech Republic)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j YALE CANCER CENTER   (United States)

more..

Author keywords

antigen cross presentation; autophagy; DC based vaccination; immunogenic cell death; regulatory T cells; Toll like receptor agonists

Indexed keywords

CD123 ANTIGEN; CD134 ANTIGEN; CD70 ANTIGEN; CD86 ANTIGEN; CYCLIN B1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE RECEPTOR 1; INTERLEUKIN 1 RECEPTOR; KIDNEY INJURY MOLECULE 1; MUCIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIPULEUCEL T; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MELANOMA; OVARY CARCINOMA; PROSTATE CARCINOMA; REVIEW; SARCOMA;

EID: 84938566015     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.963424     Document Type: Review

References (348)

1. J.Banchereau, R.M.Steinman. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588
2. R.M.Steinman, J.Banchereau. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175
3. M.Merad, P.Sathe, J.Helft, J.Miller, A.Mortha. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604; PMID:23516985; http://dx.doi.org/10.1146/annurev-immunol-020711-074950
4. A.Lanzavecchia, F.Sallusto. M.Ralph. Steinman 1943-2011. Cell 2011; 147:1216-7; PMID:22263224; http://dx.doi.org/10.1016/j.cell.2011.11.040
5. M.C.Nussenzweig, I.Mellman. Ralph Steinman (1943-2011). Nature 2011; 478:460; PMID:22031432; http://dx.doi.org/10.1038/478460a
6. I.Mellman, M.Nussenzweig. Retrospective. Ralph M. Steinman (1943-2011). Science 2011; 334:466; PMID:22034425; http://dx.doi.org/10.1126/science.1215136
7. R.M.Steinman, Z.A.Cohn. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:4573839; http://dx.doi.org/10.1084/jem.137.5.1142
8. J.Banchereau, S.Paczesny, P.Blanco, L.Bennett, V.Pascual, J.Fay, A.K.Palucka. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987:180-7; PMID:12727638; http://dx.doi.org/10.1111/j.1749-6632.2003.tb06047.x
9. + T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116:1685-97; PMID:20530286; http://dx.doi.org/10.1182/blood-2010-01-264960
10. J.Banchereau, B.Schuler-Thurner, A.K.Palucka, G.Schuler. Dendritic cells as vectors for therapy. Cell 2001; 106:271-4; PMID:11509176; http://dx.doi.org/10.1016/S0092-8674(01)00448-2
11. G.Jego, A.K.Palucka, J.P.Blanck, C.Chalouni, V.Pascual, J.Banchereau. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19:225-34; PMID:12932356; http://dx.doi.org/10.1016/S1074-7613(03)00208-5
12. A.K.Palucka, H.Ueno, J.W.Fay, J.Banchereau. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129-50; PMID:17979844; http://dx.doi.org/10.1111/j.1600-065X.2007.00575.x
13. H.Ueno, E.Klechevsky, R.Morita, C.Aspord, T.Cao, T.Matsui, T.Di Pucchio, J.Connolly, J.W.Fay, V.Pascual Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118-42; PMID:17850486; http://dx.doi.org/10.1111/j.1600-065X.2007.00551.x
14. J.Banchereau, B.Pulendran, R.Steinman, K.Palucka. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries? J Exp Med 2000; 192:F39-44; PMID:11120782; http://dx.doi.org/10.1084/jem.192.12.F39
15. + T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192:1535-44; PMID:11104796; http://dx.doi.org/10.1084/jem.192.11.1535
16. + T cells. J Exp Med 2012; 209:109-21; PMID:22213806; http://dx.doi.org/10.1084/jem.20110399
17. R.Jotwani, A.K.Palucka, M.Al-Quotub, M.Nouri-Shirazi, J.Kim, D.Bell, J.Banchereau, C.W.Cutler. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 2001; 167:4693-700; PMID:11591800; http://dx.doi.org/10.4049/jimmunol.167.8.4693
18. T.Matsui, J.E.Connolly, M.Michnevitz, D.Chaussabel, C.I.Yu, C.Glaser, S.Tindle, M.Pypaert, H.Freitas, B.Piqueras CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182:6815-23; PMID:19454677; http://dx.doi.org/10.4049/jimmunol.0802008
19. M.Nouri-Shirazi, J.Banchereau, D.Bell, S.Burkeholder, E.T.Kraus, J.Davoust, K.A.Palucka. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165:3797-803; PMID:11034385; http://dx.doi.org/10.4049/jimmunol.165.7.3797
20. A.Rolland, L.Guyon, M.Gill, Y.H.Cai, J.Banchereau, K.McClain, A.K.Palucka. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 2005; 174:3067-71; PMID:15728521; http://dx.doi.org/10.4049/jimmunol.174.5.3067
21. P.Chomarat, J.Banchereau, J.Davoust, A.K.Palucka. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1:510-4; PMID:11101873; http://dx.doi.org/10.1038/82763
22. J.Banchereau, A.K.Palucka. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306; PMID:15803149; http://dx.doi.org/10.1038/nri1592
23. P.Blanco, A.K.Palucka, M.Gill, V.Pascual, J.Banchereau. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294:1540-3; PMID:11711679; http://dx.doi.org/10.1126/science.1064890
24. B.Pulendran, K.Palucka, J.Banchereau. Sensing pathogens and tuning immune responses. Science 2001; 293:253-6; PMID:11452116; http://dx.doi.org/10.1126/science.1062060
25. S.Hambleton, S.Salem, J.Bustamante, V.Bigley, S.Boisson-Dupuis, J.Azevedo, A.Fortin, M.Haniffa, L.Ceron-Gutierrez, C.M.Bacon IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127-38; PMID:21524210; http://dx.doi.org/10.1056/NEJMoa1100066
26. B.N.Lambrecht, H.Hammad. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003; 3:994-1003; PMID:14647481; http://dx.doi.org/10.1038/nri1249
27. E.Miller, N.Bhardwaj. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 2013; 254:170-89; PMID:23772620; http://dx.doi.org/10.1111/imr.12082
28. K.Palucka, J.Banchereau. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
29. L.P.Richman, R.H.Vonderheide. Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. Oncoimmunology 2014; 3:e28610; PMID:25097801; http://dx.doi.org/10.4161/onci.28610
30. L.C.Sandin, T.H.Totterman, S.M.Mangsbo. Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer. Oncoimmunology 2014; 3:e27400; PMID:24701374; http://dx.doi.org/10.4161/onci.27400
31. J.Idoyaga, C.Fiorese, L.Zbytnuik, A.Lubkin, J.Miller, B.Malissen, D.Mucida, M.Merad, R.M.Steinman. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844-54; PMID:23298832
32. S.K.Watkins, A.A.Hurwitz. FOXO3: a master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252-4; PMID:22720261; http://dx.doi.org/10.4161/onci.1.2.18241
33. R.M.Steinman, D.Hawiger, M.C.Nussenzweig. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141040
34. L.Galluzzi, O.Kepp, G.Kroemer. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780-8; PMID:23175281; http://dx.doi.org/10.1038/nrm3479
35. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
36. M.Cirone, L.Di Renzo, L.V.Lotti, V.Conte, P.Trivedi, R.Santarelli, R.Gonnella, L.Frati, A.Faggioni. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218-9; PMID:23170286; http://dx.doi.org/10.4161/onci.20428
37. P.Jin, T.H.Han, J.Ren, S.Saunders, E.Wang, F.M.Marincola, D.F.Stroncek. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010; 8:4; PMID:20078880; http://dx.doi.org/10.1186/1479-5876-8-4
38. B.J.Quah, H.C.O’Neill. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 2005; 9:643-54; PMID:16202211; http://dx.doi.org/10.1111/j.1582-4934.2005.tb00494.x
39. T.Nakahara, Y.Moroi, H.Uchi, M.Furue. Differential role of MAPK signaling in human dendritic cell maturation and Th1Th2 engagement. J Dermatol Sci 2006; 42:1-11; PMID:16352421; http://dx.doi.org/10.1016/j.jdermsci.2005.11.004
40. G.E.Hammer, A.Ma. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu Rev Immunol 2013; 31:743-91; PMID:23330953; http://dx.doi.org/10.1146/annurev-immunol-020711-074929
41. C.Reis e Sousa. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6:476-83; PMID:16691244; http://dx.doi.org/10.1038/nri1845
42. R.M.Steinman. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; http://dx.doi.org/10.1146/annurev-immunol-100311-102839
43. + and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587-92; PMID:9927520; http://dx.doi.org/10.1084/jem.189.3.587
44. B.Pulendran, J.L.Smith, G.Caspary, K.Brasel, D.Pettit, E.Maraskovsky, E.Maraskovsky, C.R.Maliszewski. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999; 96:1036-41; PMID:9927689; http://dx.doi.org/10.1073/pnas.96.3.1036
45. D.Dudziak, A.O.Kamphorst, G.F.Heidkamp, V.R.Buchholz, C.Trumpfheller, S.Yamazaki, C.Cheong, K.Liu, H.W.Lee, C.G.Park Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-11; PMID:17204652; http://dx.doi.org/10.1126/science.1136080
46. H.Ueno, A.K.Palucka, J.Banchereau. The expanding family of dendritic cell subsets. Nat Biotechnol 2010; 28:813-5; PMID:20697407; http://dx.doi.org/10.1038/nbt0810-813
47. H.Ueno, N.Schmitt, E.Klechevsky, A.Pedroza-Gonzalez, T.Matsui, G.Zurawski, S.Oh, J.Fay, V.Pascual, J.Banchereau Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199-212; PMID:20193020; http://dx.doi.org/10.1111/j.0105-2896.2009.00884.x
48. A.T.Satpathy, X.Wu, J.C.Albring, K.M.Murphy. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145-54; PMID:23160217; http://dx.doi.org/10.1038/ni.2467
49. K.Palucka, J.Banchereau. Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013; 25:396-402; PMID:23725656; http://dx.doi.org/10.1016/j.coi.2013.05.001
50. E.Klechevsky, J.Banchereau. Human dendritic cells subsets as targets and vectors for therapy. Ann N Y Acad Sci 2013; 1284:24-30; PMID:23651190; http://dx.doi.org/10.1111/nyas.12113
51. A.Mildner, S.Jung. Development and function of dendritic cell subsets. Immunity 2014; 40:642-56; PMID:24837101; http://dx.doi.org/10.1016/j.immuni.2014.04.016
52. E.Klechevsky, R.Morita, M.Liu, Y.Cao, S.Coquery, L.Thompson-Snipes, F.Briere, D.Chaussabel, G.Zurawski, A.K.Palucka Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497-510; PMID:18789730; http://dx.doi.org/10.1016/j.immuni.2008.07.013
53. B.E.Clausen, M.J.Girard-Madoux. IL-10 control of dendritic cells in the skin. Oncoimmunology 2013; 2:e23186; PMID:23802070; http://dx.doi.org/10.4161/onci.23186
54. K.Sere, P.Felker, T.Hieronymus, M.Zenke. TGFbeta1 microenvironment determines dendritic cell development. Oncoimmunology 2013; 2:e23083; PMID:23687620; http://dx.doi.org/10.4161/onci.23083
55. + dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348
56. + dendritic cells. J Exp Med 2010; 207:1283-92; PMID:20479118; http://dx.doi.org/10.1084/jem.20100223
57. + dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID:20479116; http://dx.doi.org/10.1084/jem.20092140
58. + dendritic cells. J Exp Med 2010; 207:1261-71; PMID:20479117; http://dx.doi.org/10.1084/jem.20092618
59. O.P.Joffre, E.Segura, A.Savina, S.Amigorena. Cross-presentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254
60. + dendritic cell subset. Immunol Rev 2010; 234:18-31; PMID:20193009; http://dx.doi.org/10.1111/j.0105-2896.2009.00870.x
61. F.P.Siegal, N.Kadowaki, M.Shodell, P.A.Fitzgerald-Bocarsly, K.Shah, S.Ho, S.Antonenko, Y.J.Liu. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-7; PMID:10364556; http://dx.doi.org/10.1126/science.284.5421.1835
62. M.Cella, F.Facchetti, A.Lanzavecchia, M.Colonna. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1:305-10; PMID:11017101; http://dx.doi.org/10.1038/79747
63. M.Gilliet, A.Boonstra, C.Paturel, S.Antonenko, X.L.Xu, G.Trinchieri, A.O'Garra, Y.J.Liu. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocytemacrophage colony-stimulating factor. J Exp Med 2002; 195:953-8; PMID:11927638; http://dx.doi.org/10.1084/jem.20020045
64. + regulatory T cells. J Immunol 2004; 173:4433-42; PMID:15383574; http://dx.doi.org/10.4049/jimmunol.173.7.4433
65. L.Zitvogel, A.Tesniere, G.Kroemer. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
66. R.D.Schreiber, L.J.Old, M.J.Smyth. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
67. L.Galluzzi, L.Senovilla, L.Zitvogel, G.Kroemer. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
68. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
69. U.K.Scarlett, M.R.Rutkowski, A.M.Rauwerdink, J.Fields, X.Escovar-Fadul, J.Baird, J.R.Cubillos-Ruiz, A.C.Jacobs, J.L.Gonzalez, J.Weaver Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:22351930; http://dx.doi.org/10.1084/jem.20111413
70. +) cells. J Immunol 2010; 184:6151-60; PMID:20427766; http://dx.doi.org/10.4049/jimmunol.0903519
71. N.Chaput, R.Conforti, S.Viaud, A.Spatz, L.Zitvogel. The Janus face of dendritic cells in cancer. Oncogene 2008; 27:5920-31; PMID:18836473; http://dx.doi.org/10.1038/onc.2008.270
72. J.Taieb, N.Chaput, C.Menard, L.Apetoh, E.Ullrich, M.Bonmort, M.Péquignot, N.Casares, M.Terme, C.Flament A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12:214-9; PMID:16444265; http://dx.doi.org/10.1038/nm1356
73. Y.Ma, S.Adjemian, S.R.Mattarollo, T.Yamazaki, L.Aymeric, H.Yang, J.P.Portela Catani, D.Hannani, H.Duret Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j.immuni.2013.03.003
74. L.Senovilla, I.Vitale, I.Martins, M.Tailler, C.Pailleret, M.Michaud, L.Galluzzi, S.Adjemian, O.Kepp, M.Niso-Santano An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
75. M.Michaud, I.Martins, A.Q.Sukkurwala, S.Adjemian, Y.Ma, P.Pellegatti, S.Shen, O.Kepp, M.Scoazec, G.Mignot Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
76. +) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1:1451-3; PMID:23243626; http://dx.doi.org/10.4161/onci.21356
77. V.Sisirak, J.Faget, N.Vey, J.Y.Blay, C.Menetrier-Caux, C.Caux, N.Bendriss-Vermare. Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2:e22338; PMID:23482834; http://dx.doi.org/10.4161/onci.22338
78. L.Senovilla, E.Vacchelli, J.Galon, S.Adjemian, A.Eggermont, W.H.Fridman, C.Sautès-Fridman, Y.Ma, E.Tartour, L.Zitvogel Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
79. L.Galluzzi, L.Senovilla, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautès-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494
80. T.E.Reichert, C.Scheuer, R.Day, W.Wagner, T.L.Whiteside. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91:2136-47; PMID:11391595; http://dx.doi.org/10.1002/1097-0142(20010601)91:11%3c2136::AID-CNCR1242%3e3.0.CO;2-Q
81. M.Ikeguchi, M.Ikeda, S.Tatebe, M.Maeta, N.Kaibara. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 1998; 5:1185-9; PMID:9683832
82. S.Ishigami, S.Natsugoe, M.Matsumoto, H.Okumura, H.Sakita, S.Nakashima, S.Takao, T.Aikou. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003; 10:1237-40; PMID:12883687
83. Y.Kakeji, Y.Maehara, D.Korenaga, S.Tsujitani, M.Haraguchi, A.Watanabe, H.Orita, K.Sugimachi. Prognostic significance of tumor-host interaction in clinical gastric cancer: relationship between DNA ploidy and dendritic cell infiltration. J Surg Oncol 1993; 52:207-12; PMID:8468980; http://dx.doi.org/10.1002/jso.2930520402
84. S.Ishigami, T.Aikou, S.Natsugoe, S.Hokita, H.Iwashige, M.Tokushige, S.Sonoda. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 1998; 55:65-9; PMID:9428378; http://dx.doi.org/10.1159/000011837
85. T.Okuyama, Y.Maehara, Y.Kakeji, S.Tsuijitani, D.Korenaga, K.Sugimachi. Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer 1998; 82:1468-75; PMID:9554522; http://dx.doi.org/10.1002/(SICI)1097-0142(19980415)82:8%3c1468::AID-CNCR6%3e3.0.CO;2-5
86. S.Ishigami, S.Natsugoe, K.Tokuda, A.Nakajo, C.Xiangming, H.Iwashige, K.Aridome, S.Hokita, T.Aikou. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159:103-8; PMID:10974412; http://dx.doi.org/10.1016/S0304-3835(00)00542-5
87. H.Saito, T.Osaki, D.Murakami, T.Sakamoto, S.Kanaji, S.Ohro, S.Tatebe, S.Tsujitani, M.Ikeguchi. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123-8; PMID:17262742; http://dx.doi.org/10.1002/jso.20612
88. A.I.Daud, N.Mirza, B.Lenox, S.Andrews, P.Urbas, G.X.Gao, J.H.Lee, V.K.Sondak, A.I.Riker, R.C.Deconti Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008; 26:3235-41; PMID:18591558; http://dx.doi.org/10.1200/JCO.2007.13.9048
89. X.Y.Cai, Q.Gao, S.J.Qiu, S.L.Ye, Z.Q.Wu, J.Fan, Z.Y.Tang. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:293-301; PMID:16421755; http://dx.doi.org/10.1007/s00432-006-0075-y
90. X.Y.Yin, M.D.Lu, Y.R.Lai, L.J.Liang, J.F.Huang. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003; 50:1281-4; PMID:14571719
91. Y.Nakakubo, M.Miyamoto, Y.Cho, Y.Hida, T.Oshikiri, M.Suzuoki, K.Hiraoka, T.Itoh, S.Kondo, H.Katoh. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89:1736-42; PMID:14583778; http://dx.doi.org/10.1038/sj.bjc.6601331
92. A.Honig, N.Schaller, J.Dietl, J.Backe, U.Kammerer. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Res 2005; 25:1747-53; PMID:16033094
93. K.C.Chang, G.C.Huang, D.Jones, Y.H.Lin. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13:6666-72; PMID:18006767; http://dx.doi.org/10.1158/1078-0432.CCR-07-0504
94. M.Furihata, Y.Ohtsuki, H.Sonobe, K.Araki, T.Ogata, T.Toki, S.Ogoshi, T.Tamiya. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku J Exp Med 1993; 169:187-95; PMID:8248911; http://dx.doi.org/10.1620/tjem.169.187
95. M.Iwamoto, H.Shinohara, A.Miyamoto, M.Okuzawa, H.Mabuchi, T.Nohara, G.Gon, M.Toyoda, N.Tanigawa. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104:92-7; PMID:12532424; http://dx.doi.org/10.1002/ijc.10915
96. M.C.Dieu-Nosjean, M.Antoine, C.Danel, D.Heudes, M.Wislez, V.Poulot, N.Rabbe, L.Laurans, E.Tartour, L.de Chaisemartin Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284
97. C.Sautes-Fridman, J.Cherfils-Vicini, D.Damotte, S.Fisson, W.H.Fridman, I.Cremer, M.C.Dieu-Nosjean. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011; 30:13-25; PMID:21271351; http://dx.doi.org/10.1007/s10555-011-9279-y
98. +) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56:1459-69; PMID:17279413; http://dx.doi.org/10.1007/s00262-007-0286-3
99. M.Kobayashi, K.Suzuki, M.Yashi, M.Yuzawa, N.Takayashiki, T.Morita. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007; 27:1137-41; PMID:17465253
100. C.Conrad, M.Gilliet. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: a dangerous liaison. Oncoimmunology 2013; 2:e23887; PMID:23762788; http://dx.doi.org/10.4161/onci.23887
101. S.Ishigami, S.Ueno, M.Matsumoto, H.Okumura, T.Arigami, Y.Uchikado, T.Setoyama, H.Arima, K.Sasaki, M.Kitazono Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother 2010; 59:389-95; PMID:19760221; http://dx.doi.org/10.1007/s00262-009-0758-8
102. M.H.Sandel, A.R.Dadabayev, A.G.Menon, H.Morreau, C.J.Melief, R.Offringa, S.H.van der Burg, C.M.Janssen-van Rhijn, N.G.Ensink, R.A.Tollenaar Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005; 11:2576-82; PMID:15814636; http://dx.doi.org/10.1158/1078-0432.CCR-04-1448
103. I.Treilleux, J.Y.Blay, N.Bendriss-Vermare, I.Ray-Coquard, T.Bachelot, J.P.Guastalla, A.Bremond, S.Goddard, J.J.Pin, C.Barthelemy-Dubois Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-74; PMID:15569976; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684
104. T.O.Jensen, H.Schmidt, H.J.Moller, F.Donskov, M.Hoyer, P.Sjoegren, I.J.Christensen, T.Steiniche. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage III melanoma. Cancer 2012; 118:2476-85; PMID:21953023; http://dx.doi.org/10.1002/cncr.26511
105. S.I.Labidi-Galy, I.Treilleux, S.Goddard-Leon, J.D.Combes, J.Y.Blay, I.Ray-Coquard, C.Caux, N.Bendriss-Vermare. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012; 1:380-2; PMID:22737622; http://dx.doi.org/10.4161/onci.18801
106. L.Zitvogel, G.Kroemer. Targeting dendritic cell metabolism in cancer. Nat Med 2010; 16:858-9; PMID:20689548; http://dx.doi.org/10.1038/nm0810-858
107. V.Lombardi, O.Akbari. Dendritic cell modulation as a new interventional approach for the treatment of asthma. Drug News Perspect 2009; 22:445-51; PMID:20016853
108. J.N.Blattman, P.D.Greenberg. Cancer immunotherapy: a treatment for the masses. Science 2004; 305:200-5; PMID:15247469; http://dx.doi.org/10.1126/science.1100369
109. C.G.Figdor, I.J.de Vries, W.J.Lesterhuis, C.J.Melief. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:15122249; http://dx.doi.org/10.1038/nm1039
110. G.J.Nabel. Designing tomorrow's vaccines. N Engl J Med 2013; 368:551-60; PMID:23388006; http://dx.doi.org/10.1056/NEJMra1204186
111. C.C.Gross, H.Wiendl. Dendritic cell vaccination in autoimmune disease. Curr Opin Rheumatol 2013; 25:268-74; PMID:23370378; http://dx.doi.org/10.1097/BOR.0b013e32835cb9f2
112. S.Anguille, E.L.Smits, E.Lion, V.F.van Tendeloo, Z.N.Berneman. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
113. E.Gilboa. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203; PMID:17476349; http://dx.doi.org/10.1172/JCI31205
114. P.J.Tacken, I.J.de Vries, R.Torensma, C.G.Figdor. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173
115. Y.Satoh, C.Esche, A.Gambotto, G.V.Shurin, Z.R.Yurkovetsky, P.D.Robbins, S.C.Watkins, S.Todo, R.B.Herberman, M.T.Lotze Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2:337-49; PMID:12440225; http://dx.doi.org/10.1046/j.1359-4117.2002.01050.x
116. Y.Nishioka, M.Hirao, P.D.Robbins, M.T.Lotze, H.Tahara. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59:4035-41; PMID:10463604
117. S.C.Yang, S.Hillinger, K.Riedl, L.Zhang, L.Zhu, M.Huang, K.Atianzar, B.Y.Kuo, B.Gardner, R.K.Batra Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891-901; PMID:15102698; http://dx.doi.org/10.1158/1078-0432.CCR-03-0380
118. J.Hu, X.Yuan, M.L.Belladonna, J.M.Ong, S.Wachsmann-Hogiu, D.L.Farkas, K.L.Black, J.S.Yu. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66:8887-96; PMID:16951206; http://dx.doi.org/10.1158/0008-5472.CAN-05-3448
119. H.Endo, T.Saito, A.Kenjo, M.Hoshino, M.Terashima, T.Sato, T.Anazawa, T.Kimura, T.Tsuchiya, A.Irisawa Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2012; 19:465-75; PMID:21983893; http://dx.doi.org/10.1007/s00534-011-0457-7
120. C.X.You, M.Shi, Y.Liu, M.Cao, R.Luo, P.L.Hermonat. AAV2IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: evidence for IL-12 intracrine activity in DC. Oncoimmunology 2012; 1:847-55; PMID:23162752; http://dx.doi.org/10.4161/onci.20504
121. K.F.Bol, J.Tel, I.J.de Vries, C.G.Figdor. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology 2013; 2:e23431; PMID:23802086; http://dx.doi.org/10.4161/onci.23431
122. S.K.Nair, D.Snyder, B.T.Rouse, E.Gilboa. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70:706-15; PMID:9096653; http://dx.doi.org/10.1002/(SICI)1097-0215(19970317)70:6%3c706::AID-IJC13%3e3.0.CO;2-7
123. P.DeMatos, Z.Abdel-Wahab, C.Vervaert, D.Hester, H.Seigler. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998; 68:79-91; PMID:9624036; http://dx.doi.org/10.1002/(SICI)1096-9098(199806)68:2%3c79::AID-JSO3%3e3.0.CO;2-H
124. P.DeMatos, Z.Abdel-Wahab, C.Vervaert, H.F.Seigler. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998; 185:65-74; PMID:9636684; http://dx.doi.org/10.1006/cimm.1998.1277
125. R.C.Fields, K.Shimizu, J.J.Mule. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:9482-7; PMID:9689106; http://dx.doi.org/10.1073/pnas.95.16.9482
126. Z.Chen, T.Moyana, A.Saxena, R.Warrington, Z.Jia, J.Xiang. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptoticnecrotic tumor cells. Int J Cancer 2001; 93:539-48; PMID:11477558; http://dx.doi.org/10.1002/ijc.1365
127. S.Paczesny, S.Beranger, J.L.Salzmann, D.Klatzmann, B.M.Colombo. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 2001; 61:2386-9; PMID:11289101
128. P.Kokhaei, A.Choudhury, R.Mahdian, J.Lundin, A.Moshfegh, A.Osterborg, H.Mellstedt. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18:1810-5; PMID:15385926; http://dx.doi.org/10.1038/sj.leu.2403517
129. P.Kokhaei, M.R.Rezvany, L.Virving, A.Choudhury, H.Rabbani, A.Osterborg, H.Mellstedt. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003; 17:894-9; PMID:12750703; http://dx.doi.org/10.1038/sj.leu.2402913
130. M.L.Albert, B.Sauter, N.Bhardwaj. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; http://dx.doi.org/10.1038/32183
131. M.L.Albert, S.F.Pearce, L.M.Francisco, B.Sauter, P.Roy, R.L.Silverstein, N.Bhardwaj. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-68; PMID:9763615; http://dx.doi.org/10.1084/jem.188.7.1359
132. J.I.Mayordomo, T.Zorina, W.J.Storkus, L.Zitvogel, C.Celluzzi, L.D.Falo, C.J.Melief, S.T.Ildstad, W.M.Kast, A.B.Deleo. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302; PMID:7489412; http://dx.doi.org/10.1038/nm1295-1297
133. M.A.Ossevoort, M.C.Feltkamp, K.J.van Veen, C.J.Melief, W.M.Kast. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86-94; PMID:8574470; http://dx.doi.org/10.1097/00002371-199508000-00002
134. J.I.Mayordomo, D.J.Loftus, H.Sakamoto, C.M.De Cesare, P.M.Appasamy, M.T.Lotze, W.J.Storkus, E.Appella, A.B.DeLeo. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357-65; PMID:8666894; http://dx.doi.org/10.1084/jem.183.4.1357
135. P.Paglia, C.Chiodoni, M.Rodolfo, M.P.Colombo. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-22; PMID:8551239; http://dx.doi.org/10.1084/jem.183.1.317
136. M.F.Mackey, J.R.Gunn, C.Maliszewsky, H.Kikutani, R.J.Noelle, R.J.Barth, Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161:2094-8; PMID:9725199
137. L.Zitvogel, J.I.Mayordomo, T.Tjandrawan, A.B.DeLeo, M.R.Clarke, M.T.Lotze, W.J.Storkus. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183:87-97; PMID:8551248; http://dx.doi.org/10.1084/jem.183.1.87
138. J.I.Mayordomo, T.Zorina, W.J.Storkus, L.Zitvogel, M.D.Garcia-Prats, A.B.DeLeo, M.T.Lotze. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15:94-103; PMID:9090785; http://dx.doi.org/10.1002/stem.150094
139. N.C.Fernandez, A.Lozier, C.Flament, P.Ricciardi-Castagnoli, D.Bellet, M.Suter, M.Perricaudet, T.Tursz, E.Maraskovsky, L.Zitvogel. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi.org/10.1038/7403
140. D.Boczkowski, S.K.Nair, D.Snyder, E.Gilboa. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72; PMID:8760800; http://dx.doi.org/10.1084/jem.184.2.465
141. D.M.Ashley, B.Faiola, S.Nair, L.P.Hale, D.D.Bigner, E.Gilboa. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177-82; PMID:9314567; http://dx.doi.org/10.1084/jem.186.7.1177
142. D.Boczkowski, S.K.Nair, J.H.Nam, H.K.Lyerly, E.Gilboa. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34; PMID:10706120
143. A.S.Irvine, P.K.Trinder, D.L.Laughton, H.Ketteringham, R.H.McDermott, S.C.Reid, A.M.Haines, A.Amir, R.Husain, R.Doshi, Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 2000; 18:1273-8; PMID:11101806; http://dx.doi.org/10.1038/82383
144. E.Manickan, S.Kanangat, R.J.Rouse, Z.Yu, B.T.Rouse. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997; 61:125-32; PMID:9021916
145. W.Song, H.L.Kong, H.Carpenter, H.Torii, R.Granstein, S.Rafii, M.A.Moore, R.G.Crystal. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247-56; PMID:9334364; http://dx.doi.org/10.1084/jem.186.8.1247
146. T.Tuting, A.B.DeLeo, M.T.Lotze, W.J.Storkus. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or “self” antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27:2702-7; PMID:9368629; http://dx.doi.org/10.1002/eji.1830271033
147. Y.Wan, J.Bramson, R.Carter, F.Graham, J.Gauldie. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8:1355-63; PMID:9295130; http://dx.doi.org/10.1089/hum.1997.8.11-1355
148. J.G.McArthur, R.C.Mulligan. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998; 21:41-7; PMID:9456435; http://dx.doi.org/10.1097/00002371-199801000-00005
149. T.Ishida, S.Chada, M.Stipanov, S.Nadaf, F.I.Ciernik, D.I.Gabrilovich, D.P.Carbone. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117:244-51; PMID:10444254; http://dx.doi.org/10.1046/j.1365-2249.1999.00913.x
150. T.Tuting, J.Steitz, J.Bruck, A.Gambotto, K.Steinbrink, A.B.DeLeo, P.Robbins, J.Knop, A.H.Enk. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. J Gene Med 1999; 1:400-6; PMID:10753065; http://dx.doi.org/10.1002/(SICI)1521-2254(199911/12)1:6%3c400::AID-JGM68%3e3.0.CO;2-D
151. Y.Wan, P.Emtage, Q.Zhu, R.Foley, A.Pilon, B.Roberts, J.Gauldie. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198:131-8; PMID:10648127; http://dx.doi.org/10.1006/cimm.1999.1585
152. C.Klein, H.Bueler, R.C.Mulligan. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-708; PMID:10811863; http://dx.doi.org/10.1084/jem.191.10.1699
153. A.Ribas, L.H.Butterfield, B.Hu, V.B.Dissette, A.Y.Chen, A.Koh, S.N.Amarnani, J.A.Glaspy, W.H.McBride, J.S.Economou. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23:59-66; PMID:10687138; http://dx.doi.org/10.1097/00002371-200001000-00008
154. N.Okada, T.Saito, Y.Masunaga, Y.Tsukada, S.Nakagawa, H.Mizuguchi, K.Mori, Y.Okada, T.Fujita, T.Hayakawa Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61:7913-9; PMID:11691812
155. S.Koido, M.Kashiwaba, D.Chen, S.Gendler, D.Kufe, J.Gong. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165:5713-9; PMID:11067929; http://dx.doi.org/10.4049/jimmunol.165.10.5713
156. S.K.Nair, A.Heiser, D.Boczkowski, A.Majumdar, M.Naoe, J.S.Lebkowski, J.Vieweg, E.Gilboa. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; http://dx.doi.org/10.1038/79519
157. R.Yamanaka, S.A.Zullo, R.Tanaka, M.Blaese, K.G.Xanthopoulos. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001; 94:474-81; PMID:11235953; http://dx.doi.org/10.3171/jns.2001.94.3.0474
158. O.Insug, G.Ku, H.C.Ertl, M.Blaszczyk-Thurin. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22:613-21; PMID:12014629
159. Van S.Meirvenne, L.Straetman, C.Heirman, M.Dullaers, C.De Greef, V.Van Tendeloo, K.Thielemans. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787-97; PMID:12189529; http://dx.doi.org/10.1038/sj.cgt.7700499
160. M.Li, S.You, W.Ge, S.Ma, N.Ma, C.Zhao. Induction of T-cell immunity against leukemia by dendritic cells pulsed with total RNA isolated from leukemia cells. Chin Med J (Engl) 2003; 116:1655-61; PMID:14642130
161. T.Minami, Y.Nakanishi, M.Izumi, T.Harada, N.Hara. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 2003; 26:420-31; PMID:12973031; http://dx.doi.org/10.1097/00002371-200309000-00005
162. T.Schmidt, C.Ziske, A.Marten, S.Endres, K.Tiemann, V.Schmitz, M.Gorschlüter, C.Schneider, T.Sauerbruch, I.G.Schmidt-Wolf. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL6 pancreatic murine tumor model. Cancer Res 2003; 63:8962-7; PMID:14695214
163. C.W.Jung, J.H.Kwon, J.G.Seol, W.H.Park, J.M.Hyun, E.S.Kim, S.T.Kim, S.J.Lee, B.K.Kim, Y.Y.Lee. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. Am J Hematol 2004; 75:121-7; PMID:14978690; http://dx.doi.org/10.1002/ajh.10471
164. B.Y.Liu, X.H.Chen, Q.L.Gu, J.F.Li, H.R.Yin, Z.G.Zhu, Y.Z.Lin. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 2004; 10:630-3; PMID:14991927
165. M.Zeis, S.Siegel, A.Wagner, M.Schmitz, M.Marget, R.Kuhl-Burmeister, I.Adamzik, D.Kabelitz, P.Dreger, N.Schmitz Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170:5391-7; PMID:12759413; http://dx.doi.org/10.4049/jimmunol.170.11.5391
166. C.M.Celluzzi, L.D.Falo, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160:3081-5; PMID:9531260
167. J.Wang, S.Saffold, X.Cao, J.Krauss, W.Chen. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516-24; PMID:9820528
168. H.Tanaka, K.Shimizu, T.Hayashi, S.Shu. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002; 220:1-12; PMID:12718934; http://dx.doi.org/10.1016/S0008-8749(03)00009-1
169. R.J.Orentas, D.Schauer, Q.Bin, B.D.Johnson. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001; 213:4-13; PMID:11747351; http://dx.doi.org/10.1006/cimm.2001.1864
170. J.Kjaergaard, K.Shimizu, S.Shu. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003; 225:65-74; PMID:14698141; http://dx.doi.org/10.1016/j.cellimm.2003.09.005
171. V.L.Sukhorukov, R.Reuss, J.M.Endter, S.Fehrmann, A.Katsen-Globa, P.Gessner, A.Steinbach, K.J.Müller, A.Karpas, U.Zimmermann A biophysical approach to the optimisation of dendritic-tumour cell electrofusion. Biochem Biophys Res Commun 2006; 346:829-39; PMID:16780801; http://dx.doi.org/10.1016/j.bbrc.2006.05.193
172. D.Cathelin, A.Nicolas, A.Bouchot, J.Fraszczak, J.Labbe, B.Bonnotte. Dendritic cell-tumor cell hybrids and immunotherapy: what's next? Cytotherapy 2011; 13:774-85; PMID:21299362; http://dx.doi.org/10.3109/14653249.2011.553593
173. F.Errington, J.Jones, A.Merrick, A.Bateman, K.Harrington, M.Gough, D.O'Donnell, P.Selby, R.Vile, A.Melcher. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13:138-49; PMID:16136162; http://dx.doi.org/10.1038/sj.gt.3302609
174. L.C.Bonifaz, D.P.Bonnyay, A.Charalambous, D.I.Darguste, S.Fujii, H.Soares, M.K.Brimnes, B.Moltedo, T.M.Moran, R.M.Steinman. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220
175. + T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; http://dx.doi.org/10.1084/jem.20021598
176. D.Hawiger, K.Inaba, Y.Dorsett, M.Guo, K.Mahnke, M.Rivera, J.V.Ravetch, R.M.Steinman, M.C.Nussenzweig. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-79; PMID:11560993; http://dx.doi.org/10.1084/jem.194.6.769
177. O.Adotevi, B.Vingert, L.Freyburger, P.Shrikant, Y.C.Lone, F.Quintin-Colonna, N.Haicheur, M.Amessou, A.Herbelin, P.Langlade-Demoyen B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-9; PMID:17709554; http://dx.doi.org/10.4049/jimmunol.179.5.3371
178. P.Berraondo, C.Nouze, X.Preville, D.Ladant, C.Leclerc. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-55; PMID:17875726; http://dx.doi.org/10.1158/0008-5472.CAN-07-0321
179. P.J.Tacken, I.J.de Vries, K.Gijzen, B.Joosten, D.Wu, R.P.Rother, S.J.Faas, C.J.Punt, R.Torensma, G.J.Adema Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278-85; PMID:15878980; http://dx.doi.org/10.1182/blood-2005-01-0318
180. L.J.Cruz, P.J.Tacken, J.M.Pots, R.Torensma, S.I.Buschow, C.G.Figdor. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33:4229-39; PMID:22410170; http://dx.doi.org/10.1016/j.biomaterials.2012.02.036
181. G.Schreibelt, L.J.Klinkenberg, L.J.Cruz, P.J.Tacken, J.Tel, M.Kreutz, G.J.Adema, G.D.Brown, C.G.Figdor, I.J.de Vries. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012; 119:2284-92; PMID:22234694; http://dx.doi.org/10.1182/blood-2011-08-373944
182. P.J.Tacken, W.Ginter, L.Berod, L.J.Cruz, B.Joosten, T.Sparwasser, C.G.Figdor, A.Cambi. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011; 118:4111-9; PMID:21860028; http://dx.doi.org/10.1182/blood-2011-04-346957
183. P.J.Tacken, M.Ter Huurne, R.Torensma, C.G.Figdor. Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking. Eur J Immunol 2012; 42:1989-98; PMID:22653683; http://dx.doi.org/10.1002/eji.201142258
184. P.J.Tacken, I.S.Zeelenberg, L.J.Cruz, M.A.van Hout-Kuijer, G.van de Glind, R.G.Fokkink, A.J.Lambeck, C.G.Figdor. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi.org/10.1182/blood-2011-07-367615
185. B.Wang. Targeting dendritic cells in situ for breast cancer immunotherapy. Oncoimmunology 2012; 1:1398-400; PMID:23243606; http://dx.doi.org/10.4161/onci.20982
186. J.J.Garcia-Vallejo, W.W.Unger, H.Kalay, Y.van Kooyk. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. Oncoimmunology 2013; 2:e23040; PMID:23525136; http://dx.doi.org/10.4161/onci.23040
187. L.Zitvogel, A.Regnault, A.Lozier, J.Wolfers, C.Flament, D.Tenza, P.Ricciardi-Castagnoli, G.Raposo, S.Amigorena. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4:594-600; PMID:9585234; http://dx.doi.org/10.1038/nm0598-594
188. C.Thery, A.Regnault, J.Garin, J.Wolfers, L.Zitvogel, P.Ricciardi-Castagnoli, G.Raposo, S.Amigorena. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147:599-610; PMID:10545503; http://dx.doi.org/10.1083/jcb.147.3.599
189. S.Viaud, C.Thery, S.Ploix, T.Tursz, V.Lapierre, O.Lantz, L.Zitvogel, N.Chaput. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res 2010; 70:1281-5; PMID:20145139; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276
190. S.Munich, A.Sobo-Vujanovic, W.J.Buchser, D.Beer-Stolz, N.L.Vujanovic. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1:1074-83; PMID:23170255; http://dx.doi.org/10.4161/onci.20897
191. L.E.Kandalaft, D.J.PowellJr, C.L.Chiang, J.Tanyi, S.Kim, M.Bosch, K.Montone, R.Mick, B.L.Levine, D.A.Torigian, Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2:e22664; PMID:23482679; http://dx.doi.org/10.4161/onci.22664
192. J.Fucikova, D.Rozkova, H.Ulcova, V.Budinsky, K.Sochorova, K.Pokorna, J.Bartůňková, R.Špíšek. Poly I: c-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223; PMID:22208910; http://dx.doi.org/10.1186/1479-5876-9-223
193. J.Fucikova, P.Kralikova, A.Fialova, T.Brtnicky, L.Rob, J.Bartunkova, R.Spísek. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950
194. N.Bercovici, N.Haicheur, S.Massicard, F.Vernel-Pauillac, O.Adotevi, D.Landais, I.Gorin, C.Robert, H.M.Prince, J.J.Grob Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101-12; PMID:18157017; http://dx.doi.org/10.1097/CJI.0b013e318159f5ba
195. J.Lee, D.Boczkowski, S.Nair. Programming human dendritic cells with mRNA. Methods Mol Biol 2013; 969:111-25; PMID:23296931; http://dx.doi.org/10.1007/978-1-62703-260-5_8
196. L.T.Blalock, J.Landsberg, M.Messmer, J.Shi, A.D.Pardee, R.Haskell, L.Vujanovic, J.M.Kirkwood, L.H.Butterfield. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology 2012; 1:287-357; PMID:22737604; http://dx.doi.org/10.4161/onci.18628
197. N.K.Garg, P.Dwivedi, P.Prabha, R.K.Tyagi. RNA pulsed dendritic cells: an approach for cancer immunotherapy. Vaccine 2013; 31:1141-56; PMID:23306369; http://dx.doi.org/10.1016/j.vaccine.2012.12.027
198. S.Koido, S.Homma, M.Okamoto, Y.Namiki, K.Takakura, K.Uchiyama, M.Kajihara, S.Arihiro, H.Imazu, H.Arakawa Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2:e24437; PMID:23762810; http://dx.doi.org/10.4161/onci.24437
199. V.Apostolopoulos, T.Thalhammer, A.G.Tzakos, L.Stojanovska. Targeting antigens to dendritic cell receptors for vaccine development. J Drug Deliv 2013; 2013:869718; PMID:24228179; http://dx.doi.org/10.1155/2013/869718
200. B.Vingert, O.Adotevi, D.Patin, S.Jung, P.Shrikant, L.Freyburger, C.Eppolito, A.Sapoznikov, M.Amessou, F.Quintin-Colonna The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur J Immunol 2006; 36:1124-35; PMID:16568496; http://dx.doi.org/10.1002/eji.200535443
201. N.Haicheur, E.Bismuth, S.Bosset, O.Adotevi, G.Warnier, V.Lacabanne, A.Regnault, C.Desaymard, S.Amigorena, P.Ricciardi-Castagnoli The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J Immunol 2000; 165:3301-8; PMID:10975847; http://dx.doi.org/10.4049/jimmunol.165.6.3301
202. M.J.Copland, M.A.Baird, T.Rades, J.L.McKenzie, B.Becker, F.Reck, P.C.Tyler, N.M.Davies. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21:883-90; PMID:12547598; http://dx.doi.org/10.1016/S0264-410X(02)00536-4
203. C.L.van Broekhoven, C.R.Parish, C.Demangel, W.J.Britton, J.G.Altin. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357-65; PMID:15205352; http://dx.doi.org/10.1158/0008-5472.CAN-04-0138
204. A.Badiee, N.Davies, K.McDonald, K.Radford, H.Michiue, D.Hart, M.Kato. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007; 25:4757-66; PMID:17512099; http://dx.doi.org/10.1016/j.vaccine.2007.04.029
205. L.Yang, H.Yang, K.Rideout, T.Cho, K.I.Joo, L.Ziegler, A.Elliot, A.Walls, D.Yu, D.Baltimore Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26:326-34; PMID:18297056; http://dx.doi.org/10.1038/nbt1390
206. B.N.Hangalapura, D.Oosterhoff, J.de Groot, L.Boon, T.Tuting, A.J.van den Eertwegh, W.R.Gerritsen, V.W.van Beusechem, A.Pereboev, D.T.Curiel Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res 2011; 71:5827-37; PMID:21747119; http://dx.doi.org/10.1158/0008-5472.CAN-11-0804
207. E.E.Thacker, M.Nakayama, B.F.Smith, R.C.Bird, Z.Muminova, T.V.Strong, L.Timares, N.Korokhov, A.M.O'Neill, T.D.de Gruijl A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009; 27:7116-24; PMID:19786146; http://dx.doi.org/10.1016/j.vaccine.2009.09.055
208. N.Korokhov, T.D.de Gruijl, W.A.Aldrich, P.L.Triozzi, P.T.Banerjee, S.D.Gillies, T.J.Curiel, J.T.Douglas, R.J.Scheper, D.T.Curiel. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther 2005; 4:289-94; PMID:15753654; http://dx.doi.org/10.4161/cbt.4.3.1499
209. L.Galluzzi, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696
210. E.Vacchelli, F.Aranda, F.Obrist, A.Eggermont, J.Galon, I.Cremer, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
211. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, J.Henrik Ter Meulen, L.Zitvogel, G.Kroemer Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http://dx.doi.org/10.4161/onci.29179
212. D.Duluc, H.Joo, L.Ni, W.Yin, K.Upchurch, D.Li, Y.Xue, P.Klucar, S.Zurawski, G.Zurawski Induction and activation of human Th17 by targeting antigens to dendritic cells via dectin-1. J Immunol 2014; 192:5776-88; PMID:24835401; http://dx.doi.org/10.4049/jimmunol.1301661
213. + mucosal effector T cells via the cytokine TGF-beta. Immunity 2013; 38:818-30; PMID:23562160; http://dx.doi.org/10.1016/j.immuni.2013.03.004
214. +) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 2013; 5:172ra20; PMID:23408053; http://dx.doi.org/10.1126/scitranslmed.3004888
215. E.Vacchelli, I.Vitale, A.Eggermont, W.H.Fridman, J.Fucikova, I.Cremer, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx.doi.org/10.4161/onci.25771
216. P.W.Kantoff, C.S.Higano, N.D.Shore, E.R.Berger, E.J.Small, D.F.Penson, C.H.Redfern, A.C.Ferrari, R.Dreicer, R.B.Sims Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
217. C.S.Higano, E.J.Small, P.Schellhammer, U.Yasothan, S.Gubernick, P.Kirkpatrick, P.W.Kantoff. Sipuleucel-T. Nat Rev Drug Discov 2010; 9:513-4; PMID:20592741; http://dx.doi.org/10.1038/nrd3220
218. M.A.Cheever, C.S.Higano. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520-6; PMID:21471425; http://dx.doi.org/10.1158/1078-0432.CCR-10-3126
219. L.Galluzzi. New immunotherapeutic paradigms for castration-resistant prostate cancer. Oncoimmunology 2013; 3:e26084; http://dx.doi.org/10.4161/onci.26084
220. Y.Qiu, M.M.Yun, M.B.Xu, Y.Z.Wang, S.Yun. Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study. Int J Clin Oncol 2013; 18:657-65; PMID:22847800; http://dx.doi.org/10.1007/s10147-012-0434-4
221. S.Abediankenari, G.Janbabaei Mollae, M.Ghasemi, Y.Yousefzadeh, M.Bahrami, K.Alimoghaddam. Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells. Acta Med Iran 2013; 51:284-8; PMID:23737309
222. M.Fracol, S.Xu, R.Mick, E.Fitzpatrick, H.Nisenbaum, R.Roses, C.Fisher, J.Tchou, K.Fox, P.Zhang Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS. Ann Surg Oncol 2013; 20:3233-9; PMID:23851609; http://dx.doi.org/10.1245/s10434-013-3119-y
223. B.M.Carreno, M.Becker-Hapak, A.Huang, M.Chan, A.Alyasiry, W.R.Lie, R.L.Aft, L.A.Cornelius, K.M.Trinkaus, G.P.Linette. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013; 123:3383-94; PMID:23867552; http://dx.doi.org/10.1172/JCI68395
224. M.Kobayashi, T.Sakabe, H.Abe, M.Tanii, H.Takahashi, A.Chiba, E.Yanagida, Y.Shibamoto, M.Ogasawara, S.Tsujitani Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 2013; 17:1609-17; PMID:23877328; http://dx.doi.org/10.1007/s11605-013-2286-2
225. P.J.Schuler, M.Harasymczuk, C.Visus, A.Deleo, S.Trivedi, Y.Lei, A.Argiris, W.Gooding, L.H.Butterfield, T.L.Whiteside Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014; 20:2433-44; PMID:24583792; http://dx.doi.org/10.1158/1078-0432.CCR-13-2617
226. T.Chodon, B.Comin-Anduix, B.Chmielowski, R.C.Koya, Z.Wu, M.Auerbach, C.Ng, E.Avramis, E.Seja, A.Villanueva Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014; 20:2457-65; PMID:24634374; http://dx.doi.org/10.1158/1078-0432.CCR-13-3017
227. M.Kobayashi, S.Shimodaira, K.Nagai, M.Ogasawara, H.Takahashi, H.Abe, M.Tanii, M.Okamoto, S.Tsujitani, S.Yusa Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother 2014; 63:797-806; PMID:24777613; http://dx.doi.org/10.1007/s00262-014-1554-7
228. S.Koido, S.Homma, M.Okamoto, K.Takakura, M.Mori, S.Yoshizaki, S.Koido, S.Homma, M.Okamoto, K.Takakura Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms’ Tumor 1 (WT1)-Specific MHC Class III-Restricted Epitopes for Pancreatic Cancer. Clin Cancer Res 2014; 20:4228-39; PMID:25056373; http://dx.doi.org/10.1158/1078-0432.CCR-14-0314
229. D.B.Lowe, A.Bose, J.L.Taylor, H.Tawbi, Y.Lin, J.M.Kirkwood, W.J.Storkus. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014; 3:e27589; PMID:24734217; http://dx.doi.org/10.4161/onci.27589
230. + regulatory T-cells in advanced melanoma patients. J Transl Med 2013; 11:135; PMID:23725550; http://dx.doi.org/10.1186/1479-5876-11-135
231. D.Reyes, L.Salazar, E.Espinoza, C.Pereda, E.Castellon, R.Valdevenito, C.Huidobro, M.Inés Becker, A.Lladser, M.N.López Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 2013; 109:1488-97; PMID:23989944; http://dx.doi.org/10.1038/bjc.2013.494
232. P.P.Bapsy, B.Sharan, C.Kumar, R.P.Das, B.Rangarajan, M.Jain, V.S.Suresh Attili, S.Subramanian, S.Aggarwal, M.Srivastava Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Cytotherapy 2014; 16:234-44; PMID:24438902; http://dx.doi.org/10.1016/j.jcyt.2013.11.013
233. D.Gao, C.Li, X.Xie, P.Zhao, X.Wei, W.Sun, H.C.Liu, A.T.Alexandrou, J.Jones, R.Zhao Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One 2014; 9:e93886; PMID:24699863; http://dx.doi.org/10.1371/journal.pone.0093886
234. +) response. J Immunother Cancer 2014; 2:4; PMID:24829761; http://dx.doi.org/10.1186/2051-1426-2-4
235. S.Baek, Y.M.Kim, S.B.Kim, C.S.Kim, S.W.Kwon, Y.Kim, H.Kim, H.Lee. Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase III trial. Cell Mol Immunol 2014; PMID:24976269; http://dx.doi.org/10.1038/cmi.2014.40
236. I.Poschke, T.Lovgren, L.Adamson, M.Nystrom, E.Andersson, J.Hansson, R.Tell, G.V.Masucci, R.Kiessling. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol Immunother 2014; 63:1061-71; PMID:24993563; http://dx.doi.org/10.1007/s00262-014-1575-2
237. P.Ramanathan, S.Ganeshrajah, R.K.Raghanvan, S.S.Singh, R.Thangarajan. Development and clinical evaluation of dendritic cell vaccines for HPV related cervical cancer - a feasibility study. Asian Pac J Cancer Prev 2014; 15:5909-16; PMID:25081721; http://dx.doi.org/10.7314/APJCP.2014.15.4.1633
238. F.de Rosa, L.Ridolfi, R.Ridolfi, G.Gentili, L.Valmorri, O.Nanni, M.Petrini, L.Fiammenghi, A.M.Granato, V.Ancarani Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy andor preleukapheresis IFN-alpha in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study. J Transl Med 2014; 12:209; PMID:25053129; http://dx.doi.org/10.1186/1479-5876-12-209
239. K.Shimizu, Y.Kotera, A.Aruga, N.Takeshita, S.Katagiri, S.Ariizumi, Y.Takahashi, K.Yoshitoshi, K.Takasaki, M.Yamamoto. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother 2014; 10:970-6; PMID:24419174; http://dx.doi.org/10.4161/hv.27678
240. J.Hunyadi, C.Andras, I.Szabo, J.Szanto, K.Szluha, S.Sipka, P.Kovács, A.Kiss, G.Szegedi, I.Altorjay Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-a phase I-II study. Pathol Oncol Res 2013; PMID:24163303
241. Y.Shibamoto, M.Okamoto, M.Kobayashi, S.Ayakawa, H.Iwata, C.Sugie, Y.Mitsuishi, H.Takahashi. Immune-maximizing (IMAX) therapy for cancer: combination of dendritic cell vaccine and intensity-modulated radiation. Mol Clin Oncol 2013; 1:649-54; PMID:24649223
242. +) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. J Immunother Cancer 2014; 2:10; PMID:24883189; http://dx.doi.org/10.1186/2051-1426-2-10
243. L.Ng, W.Heck, S.Lavsa, D.Crowther, B.Atkinson, L.Xiao, J.Araujo. The lack of predictors for rapid progression in prostate cancer patients receiving sipuleucel-T. Cancers (Basel) 2013; 5:511-8; PMID:24216988; http://dx.doi.org/10.3390/cancers5020511
244. W.Hobo, L.Strobbe, F.Maas, H.Fredrix, A.Greupink-Draaisma, B.Esendam, T.de Witte, F.Preijers, H.Levenga, B.van Rees Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother 2013; 62:1381-92; PMID:23728352; http://dx.doi.org/10.1007/s00262-013-1438-2
245. A.Coosemans, A.Vanderstraeten, S.Tuyaerts, T.Verschuere, P.Moerman, Z.Berneman, I.Vergote, F.Amant, S.W.Van Gool. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res 2013; 33:3855-9; PMID:24023319
246. A.Coosemans, A.Vanderstraeten, S.Tuyaerts, T.Verschuere, P.Moerman, Z.N.Berneman, I.Vergote, F.Amant, S.W.VAN Gool. Wilms’ Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase III clinical trial. Anticancer Res 2013; 33:5495-500; PMID:24324087
247. D.Wang, B.Zhang, H.Gao, G.Ding, Q.Wu, J.Zhang, L.Liao, H.Chen. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer 2014; 14:251; PMID:24720900; http://dx.doi.org/10.1186/1471-2407-14-251
248. Y.Shindo, S.Hazama, Y.Maeda, H.Matsui, M.Iida, N.Suzuki, K.Yoshimura, T.Ueno, S.Yoshino, K.Sakai Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer. J Transl Med 2014; 12:175; PMID:24947606; http://dx.doi.org/10.1186/1479-5876-12-175
249. E.O.Vik-Mo, M.Nyakas, B.V.Mikkelsen, M.C.Moe, P.Due-Tonnesen, E.M.Suso, S.Sæbøe-Larssen, C.Sandberg, J.E.Brinchmann, E.Helseth Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013; 62:1499-509; PMID:23817721; http://dx.doi.org/10.1007/s00262-013-1453-3
250. + T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013; 2013:976383; PMID:23509826; http://dx.doi.org/10.1155/2013/976383
251. S.Wilgenhof, A.M.Van Nuffel, D.Benteyn, J.Corthals, C.Aerts, C.Heirman, I.Van Riet, A.Bonehill, K.Thielemans, B.Neyns. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013; 24:2686-93; PMID:23904461; http://dx.doi.org/10.1093/annonc/mdt245
252. J.Ren, L.Di, G.Song, J.Yu, J.Jia, Y.Zhu, Y.Yan, H.Jiang, X.Liang, L.Che Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol 2013; 15:780-8; PMID:23359185; http://dx.doi.org/10.1007/s12094-013-1001-9
253. R.Zhong, B.Han, H.Zhong. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol 2014; 35:987-94; PMID:24006222; http://dx.doi.org/10.1007/s13277-013-1132-1
254. Y.Cui, X.Yang, W.Zhu, J.Li, X.Wu, Y.Pang. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett 2013; 6:537-41; PMID:24137363
255. Z.X.Wang, J.X.Cao, M.Wang, D.Li, Y.X.Cui, X.Y.Zhang, J.L.Liu, J.L.Li. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy 2014; 16:934-45; PMID:24794183; http://dx.doi.org/10.1016/j.jcyt.2014.02.011
256. K.Hasumi, Y.Aoki, R.Wantanabe, D.L.Mann. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy. Oncoimmunology 2013; 2:e26381; PMID:24349874; http://dx.doi.org/10.4161/onci.26381
257. M.V.Dhodapkar, M.Sznol, B.Zhao, D.Wang, R.D.Carvajal, M.L.Keohan, E.Chuang, R.E.Sanborn, J.Lutzky, J.Powderly Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:24739759; http://dx.doi.org/10.1126/scitranslmed.3008068
258. S.Vassilaros, A.Tsibanis, A.Tsikkinis, G.A.Pietersz, I.F.McKenzie, V.Apostolopoulos. Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 2013; 5:1177-82; PMID:24188672; http://dx.doi.org/10.2217/imt.13.126
259. V.T.Ho, H.T.Kim, G.Kao, C.Cutler, J.Levine, J.Rosenblatt, R.Joyce, J.H.Antin, R.J.Soiffer, J.Ritz Sequential infusion of donor derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2014; 89:1092-6; PMID:25132538; http://dx.doi.org/10.1002/ajh.23825
260. T.Takeda, T.Takeda, M.Etani, S.Kobayashi, H.Takeda. [The effect of immunotherapy and hyperthermia on patients with advanced or recurrent breast cancer]. Gan To Kagaku Ryoho 2013; 40:1596-9; PMID:24393860
261. J.Liu, J.Li, Y.Fan, K.Chang, X.Yang, W.Zhu, X.Wu, Y.Pang. Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases. Ir J Med Sci 2014; PMID:24876093
262. E.Vacchelli, I.Vitale, E.Tartour, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
263. N.Bloy, J.Pol, G.Manic, I.Vitale, A.Eggermont, J.Galon, T.Eric, Z.Laurence, K.Guido, G.Lorenzo. Trial watch: radioimmunotherapy for oncological indications. Oncoimmunology 2014; DOI: 10.4161/21624011.2014.954929
264. + T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology 2013; 2:e23429; PMID:23802084; http://dx.doi.org/10.4161/onci.23429
265. Z.Wang, M.D.Hall, K.A.Rewers-Felkins, I.S.Quinlin, S.E.Wright. Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer. Oncoimmunology 2013; 2:e23335; PMID:23526065; http://dx.doi.org/10.4161/onci.23335
266. A.M.Grimaldi, E.Simeone, D.Giannarelli, P.Muto, S.Falivene, V.Borzillo, F.M.Giugliano, F.Sandomenico, A.Petrillo, M.Curvietto Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology 2014; 3:e28780; PMID:25083318; http://dx.doi.org/10.4161/onci.28780
267. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, W.H.Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
268. M.V.Dhodapkar, K.M.Dhodapkar. Recent advances and new opportunities for targeting human dendritic cells in situ. Oncoimmunology 2014; 3(8); DOI: 10.4161/21624011.2014.954832
269. +) T cell tolerance. J Exp Med 2014; 211:1153-66; PMID:24842370; http://dx.doi.org/10.1084/jem.20132000
270. P.Arora, A.Baena, K.O.Yu, N.K.Saini, S.S.Kharkwal, M.F.Goldberg, S.Kunnath-Velayudhan, L.J.Carreño, M.M.Venkataswamy, J.Kim A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 2014; 40:105-16; PMID:24412610; http://dx.doi.org/10.1016/j.immuni.2013.12.004
271. B.U.Schraml, J.van Blijswijk, S.Zelenay, P.G.Whitney, A.Filby, S.E.Acton, N.C.Rogers, N.Moncaut, J.J.Carvajal, C.Reis e Sousa. Genetic tracing via DNGR-1 expression history defines dendritic cells as a hematopoietic lineage. Cell 2013; 154:843-58; PMID:23953115; http://dx.doi.org/10.1016/j.cell.2013.07.014
272. C.A.Klebanoff, S.P.Spencer, P.Torabi-Parizi, J.R.Grainger, R.Roychoudhuri, Y.Ji, M.Sukumar, P.Muranski, C.D.Scott, J.A.Hall Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. J Exp Med 2013; 210:1961-76; PMID:23999499; http://dx.doi.org/10.1084/jem.20122508
273. K.Baker, T.Rath, M.B.Flak, J.C.Arthur, Z.Chen, J.N.Glickman, I.Zlobec, E.Karamitopoulou, M.D.Stachler, R.D.Odze Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity 2013; 39:1095-107; PMID:24290911; http://dx.doi.org/10.1016/j.immuni.2013.11.003
274. P.Muller, K.Martin, S.Theurich, J.Schreiner, S.Savic, G.Terszowski, D.Lardinois, V.A.Heinzelmann-Schwarz, M.Schlaak, H.M.Kvasnicka Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res 2014; 2:741-55; PMID:24916470; http://dx.doi.org/10.1158/2326-6066.CIR-13-0198
275. M.Baghdadi, A.Yoneda, T.Yamashina, H.Nagao, Y.Komohara, S.Nagai, H.Akiba, M.Foretz, H.Yoshiyama, I.Kinoshita TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 2013; 39:1070-81; PMID:24315994; http://dx.doi.org/10.1016/j.immuni.2013.09.014
276. S.Rao, L.Tortola, T.Perlot, G.Wirnsberger, M.Novatchkova, R.Nitsch, P.Sykacek, L.Frank, D.Schramek, V.Komnenovic A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014; 5:3056; PMID:24445999; http://dx.doi.org/10.1038/ncomms4056
277. J.Y.Guo, G.Karsli-Uzunbas, R.Mathew, S.C.Aisner, J.J.Kamphorst, A.M.Strohecker, G.Chen, S.Price, W.Lu, X.Teng Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27:1447-61; PMID:23824538; http://dx.doi.org/10.1101/gad.219642.113
278. M.T.Rosenfeldt, J.O’Prey, J.P.Morton, C.Nixon, G.MacKay, A.Mrowinska, A.Au, T.S.Rai, L.Zheng, R.Ridgway p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504:296-300; PMID:24305049; http://dx.doi.org/10.1038/nature12865
279. D.R.Green, L.Galluzzi, G.Kroemer. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011; 333:1109-12; PMID:21868666; http://dx.doi.org/10.1126/science.1201940
280. A.Ko, A.Kanehisa, I.Martins, L.Senovilla, C.Chargari, D.Dugue, G.Mariño, O.Kepp, M.Michaud, J.L.Perfettini Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 2014; 21:92-9; PMID:24037090; http://dx.doi.org/10.1038/cdd.2013.124
281. L.Galluzzi, I.Vitale, J.M.Abrams, E.S.Alnemri, E.H.Baehrecke, M.V.Blagosklonny, T.M.Dawson, V.L.Dawson, W.S.El-Deiry, S.Fulda Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on cell death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96
282. L.Galluzzi, J.M.Bravo-San Pedro, I.Vitale, S.A.Aaronson, J.M.Abrams, D.Adam, E.S.Alnemri, L.Altucci, D.Andrews, M.Annicchiarico-Petruzzelli Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2015:in press; PMID:25236395; http://dx.doi.org/10.1038/cdd.2014.137
283. A.D.Garg, A.M.Dudek, P.Agostinis. Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity. Oncoimmunology 2013; 2:e26260; PMID:24353910; http://dx.doi.org/10.4161/onci.26260
284. Y.Ma, S.Adjemian, H.Yang, J.P.Catani, D.Hannani, I.Martins, M.Michaud, O.Kepp, A.Q.Sukkurwala, E.Vacchelli ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology 2013; 2:e24568; PMID:23894718; http://dx.doi.org/10.4161/onci.24568
285. G.Kroemer, L.Galluzzi, L.Zitvogel. Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology 2013; 2:e27158; PMID:24498568; http://dx.doi.org/10.4161/onci.27158
286. E.D.Mortenson, Y.X.Fu. Anti-HER2Neu passive-aggressive immunotherapy. Oncoimmunology 2014; 3:e27296; PMID:24605268; http://dx.doi.org/10.4161/onci.27296
287. M.Moschovi, G.A.Alexiou, A.Patereli, K.Stefanaki, I.Doussis-Anagnostopoulou, A.Stofas, G.Sfakianos, N.Prodromou. Prognostic significance of cyclin A and B1 in pediatric embryonal tumors. J Neurooncol 2011; 103:699-704; PMID:21069428; http://dx.doi.org/10.1007/s11060-010-0451-y
288. R.S.Andersen, R.B.Sorensen, C.Ritter, I.M.Svane, J.C.Becker, P.thor Straten, M.H.Andersen. Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol Immunother 2011; 60:227-34; PMID:20981424; http://dx.doi.org/10.1007/s00262-010-0933-y
289. E.M.Tyler, G.Koehne. The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft-vs.- myeloma effect. Oncoimmunology 2013; 2:e24963; PMID:24073375; http://dx.doi.org/10.4161/onci.24963
290. C.Wang, J.Xie, J.Guo, H.C.Manning, J.C.Gore, N.Guo. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep 2012; 28:1301-8; PMID:22895640
291. C.Tsurumi, N.Esser, E.Firat, S.Gaedicke, M.Follo, M.Behe, U.Elsässer-Beile, A.L.Grosu, R.Graeser, G.Niedermann. Non-invasive in vivo imaging of tumor-associated CD133prominin. PLoS One 2010; 5:e15605; PMID:21187924; http://dx.doi.org/10.1371/journal.pone.0015605
292. N.J.Gay, M.F.Symmons, M.Gangloff, C.E.Bryant. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 2014; 14:546-58; PMID:25060580; http://dx.doi.org/10.1038/nri3713
293. G.Trinchieri, A.Sher. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7:179-90; PMID:17318230; http://dx.doi.org/10.1038/nri2038
294. A.M.Krieg. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84; PMID:16763660; http://dx.doi.org/10.1038/nrd2059
295. A.J.Simpson, O.L.Caballero, A.Jungbluth, Y.T.Chen, L.J.Old. Cancertestis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5:615-25; PMID:16034368; http://dx.doi.org/10.1038/nrc1669
296. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
297. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, E.Tartour, L.Zitvogel, G.Kroemer Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344
298. M.H.Kershaw, J.A.Westwood, P.K.Darcy. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13:525-41; PMID:23880905; http://dx.doi.org/10.1038/nrc3565
299. S.A.Rosenberg, N.P.Restifo, J.C.Yang, R.A.Morgan, M.E.Dudley. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
300. T.A.Yap, C.P.Carden, S.B.Kaye. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9:167-81; PMID:19238149; http://dx.doi.org/10.1038/nrc2583
301. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
302. Bevacizumab in ovarian cancer. Nat Rev Cancer 2012; 12:83; PMID:22270952; http://dx.doi.org/10.1038/nrc3213
303. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
304. W.J.Lesterhuis, J.B.Haanen, C.J.Punt. Cancer immunotherapy–revisited. Nat Rev Drug Discov 2011; 10:591-600; PMID:21804596; http://dx.doi.org/10.1038/nrd3500
305. O.L.Chinot, W.Wick, W.Mason, R.Henriksson, F.Saran, R.Nishikawa, A.F.Carpentier, K.Hoang-Xuan, P.Kavan, D.Cernea Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370:709-22; PMID:24552318; http://dx.doi.org/10.1056/NEJMoa1308345
306. R.Stupp, W.P.Mason, M.J.van den Bent, M.Weller, B.Fisher, M.J.Taphoorn, K.Belanger, A.A.Brandes, C.Marosi, U.Bogdahn Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
307. G.Chen, G.Han, B.Shen, Y.Li. GM-CSF facilitates the development of inflammation-associated colorectal carcinoma. Oncoimmunology 2014; 3:e28186; PMID:24778929; http://dx.doi.org/10.4161/onci.28186
308. N.Obermajer, P.Kalinski. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology 2012; 1:762-4; PMID:22934275; http://dx.doi.org/10.4161/onci.19681
309. G.A.FitzGerald, C.Patrono. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-42; PMID:11496855; http://dx.doi.org/10.1056/NEJM200108093450607
310. C.Ming Lim, R.Stephenson, A.M.Salazar, R.L.Ferris. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013; 2:e24677; PMID:23894722; http://dx.doi.org/10.4161/onci.23187
311. S.Sharma, L.Zhu, M.Davoodi, M.Harris-White, J.M.Lee, M.St John, R.Salgia, S.Dubinett. TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets 2013; 17:481-3; PMID:23506058; http://dx.doi.org/10.1517/14728222.2013.781585
312. C.F.Nicodemus, J.S.Berek. TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010; 2:137-40; PMID:20635920; http://dx.doi.org/10.2217/imt.10.8
313. S.A.Gujar, D.Clements, P.W.Lee. Two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:24804161; http://dx.doi.org/10.4161/onci.27622
314. T.J.Waldron, J.G.Quatromoni, T.A.Karakasheva, S.Singhal, A.K.Rustgi. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology 2013; 2:e24117; PMID:23734336; http://dx.doi.org/10.4161/onci.24117
315. C.Hotz, C.Bourquin. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: timing is everything. Oncoimmunology 2012; 1:227-8; PMID:22720251; http://dx.doi.org/10.4161/onci.1.2.18169
316. S.Demaria, C.Vanpouille-Box, S.C.Formenti, S.Adams. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology 2013; 2:e25997; PMID:24404422; http://dx.doi.org/10.4161/onci.25997
317. Z.J.Li, K.C.Sohn, D.K.Choi, G.Shi, D.Hong, H.E.Lee, K.U.Whang, Y.H.Lee, M.Im, Y.Lee Roles of TLR7 in activation of NF-kappaB signaling of keratinocytes by imiquimod. PLoS One 2013; 8:e77159; PMID:24146965; http://dx.doi.org/10.1371/journal.pone.0077159
318. M.Holcmann, B.Drobits, M.Sibilia. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661-3; PMID:23264929; http://dx.doi.org/10.4161/onci.22033
319. B.Drobits, M.Holcmann, N.Amberg, M.Swiecki, R.Grundtner, M.Hammer, M.Colonna, M.Sibilia. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122:575-85; PMID:22251703; http://dx.doi.org/10.1172/JCI61034
320. R.Okuyama, A.Aruga, T.Hatori, K.Takeda, M.Yamamoto. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013; 2:e27010; PMID:24498547; http://dx.doi.org/10.4161/onci.27010
321. A.Suri, S.Saini, A.Sinha, S.Agarwal, A.Verma, D.Parashar, S.Singh, N.Gupta, N.Jagadish. Cancer testis antigens: a new paradigm for cancer therapy. Oncoimmunology 2012; 1:1194-6; PMID:23170277; http://dx.doi.org/10.4161/onci.20686
322. P.Kulkarni, T.Shiraishi, K.Rajagopalan, R.Kim, S.M.Mooney, R.H.Getzenberg. Cancertestis antigens and urological malignancies. Nat Rev Urol 2012; 9:386-96; PMID:22710665; http://dx.doi.org/10.1038/nrurol.2012.117
323. J.J.Sznurkowski, A.Zawrocki, J.Karczewska, J.Emerich, W.Biernat. Should we consider cancertestis antigens NY-ESO-1, MAGE-A4 and MAGE-A1 as potential targets for immunotherapy in vulvar squamous cell carcinoma? Histopathology 2011; 58:481-3; PMID:21323970; http://dx.doi.org/10.1111/j.1365-2559.2011.03772.x
324. A.W.Turksma, H.J.Bontkes, J.J.Ruizendaal, K.B.Scholten, J.Akershoek, S.Rampersad, L.M.Moesbergen, S.A.Cillessen, S.J.Santegoets, T.D.de Gruijl Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med 2013; 11:152; PMID:23787039; http://dx.doi.org/10.1186/1479-5876-11-152
325. E.R.Manuel, C.A.Blache, J.D.Ellenhorn, D.J.Diamond. Survivin the battle against immunosuppression. Oncoimmunology 2012; 1:240-1; PMID:22720256; http://dx.doi.org/10.4161/onci.1.2.18180
326. D.C.Altieri. Targeting survivin in cancer. Cancer Lett 2013; 332:225-8; PMID:22410464; http://dx.doi.org/10.1016/j.canlet.2012.03.005
327. J.Jiang, C.Wu, B.Lu. Cytokine-induced killer cells promote antitumor immunity. J Transl Med 2013; 11:83; PMID:23536996; http://dx.doi.org/10.1186/1479-5876-11-83
328. S.Rutella, F.Locatelli. Is there a role for cytokine-induced killer cells in cancer immunotherapy? Immunotherapy 2012; 4:867-9; PMID:23046228; http://dx.doi.org/10.2217/imt.12.89
329. D.Sangiolo. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2011; 2:363-8; PMID:21716717; http://dx.doi.org/10.7150/jca.2.363
330. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/; http://dx.doi.org/10.4161/onci.24238
331. L.Galluzzi, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549
332. R.H.Vonderheide, J.M.Burg, R.Mick, J.A.Trosko, D.Li, M.N.Shaik, A.W.Tolcher, O.Hamid. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:23483678; http://dx.doi.org/10.4161/onci.23033
333. N.J.Vogelzang. Enzalutamide–a major advance in the treatment of metastatic prostate cancer. N Engl J Med 2012; 367:1256-7; PMID:23013078; http://dx.doi.org/10.1056/NEJMe1209041
334. H.I.Scher, K.Fizazi, F.Saad, M.E.Taplin, C.N.Sternberg, K.Miller, R.de Wit, P.Mulders, K.N.Chi, N.D.Shore Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187-97; PMID:22894553; http://dx.doi.org/10.1056/NEJMoa1207506
335. E.Raymond, A.Dalgleish, J.E.Damber, M.Smith, R.Pili. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol 2014; 73:1-8; PMID:24162378; http://dx.doi.org/10.1007/s00280-013-2321-8
336. S.Osanto, H.van Poppel, J.Burggraaf. Tasquinimod: a novel drug in advanced prostate cancer. Future Oncol 2013; 9:1271-81; PMID:23980674; http://dx.doi.org/10.2217/fon.13.136
337. S.George, R.Pili. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep 2013; 15:65-8; PMID:23334511; http://dx.doi.org/10.1007/s11912-013-0295-7
338. N.Chaput, C.Flament, C.Locher, M.Desbois, A.Rey, S.Rusakiewicz, V.Poirier-Colame, P.Pautier, A.Le Cesne, J.C.Soria Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome. Oncoimmunology 2013; 2:e23080; PMID:23525357; http://dx.doi.org/10.4161/onci.23080
339. P.Pautier, C.Locher, C.Robert, A.Deroussent, C.Flament, A.Le Cesne, A.Rey, R.Bahleda, V.Ribrag, J.C.Soria Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate. Oncoimmunology 2013; 2:e23079; PMID:23525192; http://dx.doi.org/10.4161/onci.23079
340. L.Boissel, M.Betancur-Boissel, W.Lu, D.S.Krause, R.A.Van Etten, W.S.Wels, H.Klingemann. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2013; 2:e26527; PMID:24404423; http://dx.doi.org/10.4161/onci.26527
341. D.G.Maloney. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366:2008-16; PMID:22621628; http://dx.doi.org/10.1056/NEJMct1114348
342. E.M.Riedmann. CDX-1401 combined with TLR agonist: positive phase 1 results. Hum Vaccin Immunother 2012; 8:1742
343. C.Riediger, G.Wingender, P.Knolle, S.Aulmann, W.Stremmel, J.Encke. Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALBc mouse model. J Cancer Res Clin Oncol 2013; 139:2097-110; PMID:24114287; http://dx.doi.org/10.1007/s00432-013-1532-z
344. + T helper cell-mediated experimental autoimmune myocarditis. Vaccine 2013; 31:4802-11; PMID:23948227; http://dx.doi.org/10.1016/j.vaccine.2013.07.084
345. A.Kretz-Rommel, F.Qin, N.Dakappagari, R.Torensma, S.Faas, D.Wu, K.S.Bowdish. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 2007; 30:715-26; PMID:17893564; http://dx.doi.org/10.1097/CJI.0b013e318135472c
346. C.F.Pereira, R.Torensma, K.Hebeda, A.Kretz-Rommel, S.J.Faas, C.G.Figdor, G.J.Adema. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model. J Immunother 2007; 30:705-14; PMID:17893563; http://dx.doi.org/10.1097/CJI.0b013e31812e6256
347. R.M.Prins, X.Wang, H.Soto, E.Young, D.N.Lisiero, B.Fong, R.Everson, W.H.Yong, A.Lai, G.Li Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother 2013; 36:152-7; PMID:23377664; http://dx.doi.org/10.1097/CJI.0b013e3182811ae4
348. J.Dannull, N.R.Haley, G.Archer, S.Nair, D.Boczkowski, M.Harper, N.De Rosa, N.Pickett, P.J.Mosca, J.Burchette Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 2013; 123:3135-45; PMID:23934126; http://dx.doi.org/10.1172/JCI67544